Is KERX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

4,234 people get KERX articles and Market Currents by email alert.

Get email alerts on KERX »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
PropThink • Tue, Jun 4
Keryx: Attractive In Front Of Catalyst-Rich Second Half
PropThink • Thu, May 30 • 2 Comments
Keryx: A Small Biotech With Many Catalysts
George Rho • Wed, May 8 • 11 Comments
Whisper Number Impact: Earnings Preview For Keryx Biopharmaceuticals
WhisperNumber • Tue, May 7 • 1 Comment
Keryx, Zerenex And IP Protection: A PropThink Conference Call
PropThink • Mon, Apr 22 • 1 Comment
Keryx BioPharmaceuticals: A Favorite Of Mine In The Pharmacology World
Carl Cachia • Mon, Apr 22 • 9 Comments
Here Are The Reasons To Own Keryx And Why Catalysts Are De-Risked
PropThink • Fri, Apr 12 • 1 Comment
What You Need To Know About Keryx And Zerenex's IP
PropThink • Mon, Apr 8 • 4 Comments
The Validity And Risk Of Keryx Biopharmaceuticals
John Eastman • Wed, Mar 20 • 9 Comments
Zerenex Patent Protection Is Key For Keryx Upside, But EU Exclusivity Provides A Base
PropThink • Wed, Mar 13 • 4 Comments
Another Round On Keryx
InvestorR • Mon, Mar 4 • 8 Comments
Keryx Pharmaceuticals: In Or Out?
Zhen Lu • Tue, Feb 12 • 11 Comments
Market Noise Masks Real Potential For Keryx
PropThink • Thu, Feb 7 • 21 Comments
A Closer Look At Keryx Biopharmaceuticals' Phase III Result Announcement
InvestorR • Mon, Feb 4 • 17 Comments
Research Report Misses The Mark - A Second Chance To Own Keryx
PropThink • Mon, Feb 4 • 4 Comments
Keryx Biopharmaceuticals: Time To Get Short
EnhydrisPECorp • Mon, Feb 4 • 14 Comments
Is Keryx Biopharmaceuticals A Good Buy At $9+?
InvestorR • Thu, Jan 31 • 72 Comments
Keryx: Take The Money And Run?
Brian L. Wilson • Wed, Jan 30 • 13 Comments
Game Changing Zerenex Results, More Than 1 Year In Cash - Keryx To Trade Higher
PropThink • Mon, Jan 28 • 9 Comments
Zerenex Phase III Data Imminent; Odds Still High For Keryx To Succeed With This Drug
PropThink • Tue, Jan 22 • 17 Comments

To learn more about Seeking Alpha Pro, click here.

Rexahn's Oncology Platform Led By Its Akt-1 Inhibitor Challenges Big Pharma With Ground-Breaking Cancer Therapy
Sharon di Stefano • Wed, Jun 5 • 11 Comments
Clovis Among Top Small-Cap Biotech Picks By Legendary Fund Managers In Q1/2013
GuruFundPicks • Tue, Jun 4
BioDelivery Sciences Primed To Grab Its Share Of The $1.5 Billion Opioid Market
Scott Matusow • Tue, May 28 • 20 Comments
A Review Of Upcoming Catalysts For Kidney Disease Biotech Players In 2013
Tech Guru • Fri, May 24 • 1 Comment
Weekly Stock Watch - Week Of May 13, 2013
VFC's Stock House • Sat, May 11 • 2 Comments
Recent Noteworthy Institutional 5% Ownership Filings In Healthcare Sector
GuruFundPicks • Thu, May 9 • 5 Comments
NewLink Genetics: Looking To Join The Industry's Largest Movers
A John Hodge • Mon, Apr 29 • 3 Comments
Best Performing Russell 3,000 Stocks YTD
Bespoke Investment Group • Sun, Apr 14 • 2 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Wed, Apr 10
Biotech's Fallen Angels: Identifying Irrational Market Behavior
Logical Assessment • Mon, Apr 8 • 5 Comments
Are Any Of Your Stocks Members Of The Triple Digit Club?
Bespoke Investment Group • Fri, Mar 29 • 15 Comments
Chelsea Therapeutics: A Shoe-In For FDA Approval, Shares Could Double From Here
Shane Blackmon • Tue, Mar 26 • 11 Comments
These 4 Biotech Stocks Have Upside, Says Burrill's Senior Analyst
Ben Yoffe • Mon, Mar 25 • 4 Comments
Rockwell May Rise On Positive Phase III Results In July
Neil Danics • Thu, Mar 21 • 1 Comment
5 Investing Tricks Of The Trade For Your Arsenal
Quoth the Raven • Mon, Mar 18 • 56 Comments
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Mon, Mar 4 • 1 Comment
Weekly Stock Watch, Week Of March 4
VFC's Stock House • Mon, Mar 4
Best Performing U.S. Stocks YTD Through February
Bespoke Investment Group • Fri, Mar 1 • 2 Comments
A Biotech Winner For 2013
Equity Options Guru • Thu, Feb 21 • 15 Comments
Best-Performing Russell 3000 Stocks Year To Date
Bespoke Investment Group • Mon, Feb 11

Keryx Biopharmaceutical's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Keryx Biopharmaceuticals' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 12
Keryx Biopharmaceuticals' CEO Presents at Citi 2013 Global Healthcare Conference (Transcript)
Wed, Feb 27
Keryx Biopharmaceuticals' CEO Presents at Top-Line Results from Zerenex(TM) Phase 3 Long-Term Study Conference (Transcript)
Mon, Jan 28
Keryx Biopharmaceuticals' CEO Presents at 31st Annual J.P. Morgan Healthcare Conference (Transcript)
Thu, Jan 10
Keryx Biopharmaceuticals' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Keryx Biopharmaceuticals' CEO Presents at UBS Global Life Sciences Conference (Transcript)
Thu, Sep 20, 2012 • 2 Comments
Keryx Biopharmaceuticals' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012
Keryx Biopharmaceuticals, Inc. Q2 2008 Earnings Call Transcript
Mon, Aug 11, 2008
Keryx Biopharmaceuticals, Inc. Q1 2008 Earnings Call Transcript
Sat, May 31, 2008

Keryx Biopharmaceuticals, Inc. Announces Zerenex™ Phase 3 Data Presented at the 2013 World Congress of Nephrology

PR Newswire (Jun 3, 2013)
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2013 Financial Results

PR Newswire (May 7, 2013)
Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2013 Financial Results

PR Newswire (May 6, 2013)
Keryx Biopharmaceuticals to Present at the 25th Annual ROTH Conference

PR Newswire (Mar 14, 2013)
Keryx Biopharmaceuticals Announces Appointment of Amit Sharma, M.D. as Vice President, Medical Affairs

PR Newswire (Mar 13, 2013)
Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2012 Financial Results

PR Newswire (Mar 11, 2013)
Keryx Biopharmaceuticals, Inc. To Host Conference Call on Fourth Quarter and Year-End 2012 Financial Results

PR Newswire (Mar 11, 2013)
Cramer's Homework: Steer Clear of These 2 Troubled Stocks

at CNBC.com (Mar 8, 2013)
Keryx Biopharmaceuticals to Present at the Citigroup 2013 Global Healthcare Conference

PR Newswire (Feb 22, 2013)
Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET

PR Newswire (Feb 8, 2013)
Lightning Round: Southern Copper, Oneok & More

at CNBC.com (Jan 31, 2013)
Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock

PR Newswire (Jan 30, 2013)
Keryx Biopharmaceuticals Announces $55 Million Proposed Public Offering of Common Stock

PR Newswire (Jan 29, 2013)
Movers & Shakers: Monday’s movers: Herbalife clobbered on FTC news

at MarketWatch.com (Jan 28, 2013)
Keryx Biopharmaceuticals Announces Zerenex™ (ferric citrate) Meets Primary and All Key Secondary Endpoints in Phase 3 Long-Term Study as a Treatment for Hyperphosphatemia in End-Stage Renal Disease Patients on Dialysis

PR Newswire (Jan 28, 2013)
Keryx Biopharmaceuticals to Hold Conference Call Tomorrow at 8:00 AM ET to Discuss Top-Line Results from Zerenex™ Phase 3 Long-Term Study

PR Newswire (Jan 27, 2013)
Keryx Biopharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference

PR Newswire (Jan 7, 2013)
Keryx Biopharmaceuticals Announces Filing of New Drug Application for Marketing Approval of Ferric Citrate (Zerenex™) in Japan by Partner, Japan Tobacco Inc.

PR Newswire (Jan 7, 2013)
Keryx Biopharmaceuticals Announces that Congress Delays Implementation of Oral-Only ESRD-Related Drugs, Including Phosphate Binders, in the Bundled ESRD Prospective Payment System by Two-Years, until January 2016

PR Newswire (Jan 3, 2013)
Keryx Biopharmaceuticals to Present at The Oppenheimer & Co. Inc. 23rd Annual Healthcare Conference

PR Newswire (Dec 10, 2012)

KERX vs. ETF Alternatives

Company Description

We are a biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. We are developing Zerenex™ (ferric citrate), an oral,... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 3, 8:59 AM Keryx (KERX) presents updated data from the Phase III trial of its Zerenex drug for patients undergoing dialysis, saying that the results show "that Zerenex is an efficacious and safe oral phosphate binder." CEO Ron Bentsur makes sure to mention that the results "further highlight Zerenex's highly-differentiated product profile." There's much concern that Keryx won't be able to protect Zerenex from generic challenges. Shares +4.4%. (PR) Comment! [Healthcare]
Tuesday, May 7, 7:18 PM Keryx (KERX): Q1 EPS of -$0.03 misses by $0.02. Revenue of $7M beats by $1.17M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, April 9, 1:33 PM Keryx Biopharmaceuticals (KERX +10.9%) trades up on news that a leading patent lawyer will give an opinion on the patent position of it's Zerenex. Concern is that KERX won't be able to protect the phosphate binder from generic challengers. Comment! [Healthcare, On the Move]
Wednesday, March 13, 9:45 AM Keryx Biopharmaceuticals (KERX -0.6%) hires hypertension specialist Amit Sharma to the newly created position of VP of Medical Affairs. The appointment of Sharma, who has a broad-based background in chronic kidney disease and dialysis, comes as Keryx prepares to seek FDA approval for its Zerenex treatment for patients undergoing dialysis. (PR) Comment! [Healthcare]
Friday, March 1, 1:01 PM Midday top 10 gainers: GMXR +56%. RVLT +37%. MTG +24%. ANAC +15%. DECK +14%. NSPH +13%. KERX +13%. ATEC +13%. CRIS +12%. CIDM +12%.
Midday top 10 losers: SCMR -73%. AT -29%. RNIN -23%. LTBR -23%. FWLT -17%. MDR -14%. SUP -13%. SHIP -13%. MNOV -12%. CBMX -12%. Comment! [On the Move]
Monday, February 4, 8:44 AM JMP Securities' Jason Butler jumps to Keryx's (KERX -0.7%) defense today after the stock plummeted 22% on Friday following a report from research firm IPD Analytics that questioned whether the FDA will grant the company New Chemical Entity status for its Zerenex treatment for patients undergoing dialysis. IDP reckons that the active ingredient in Zerenex may be too similar to an existing chemical called Ferriseltz, although Butler begs to differ. 2 Comments [Healthcare, On the Move]
Friday, February 1, 12:45 PM Midday top 10 gainers: OTT +31%. ALIM +25%. BBW +22%. ADNC +21%. PSDV +16%. EDAP +16%. ABAX +15%. CRR +14%. CIS +11%. PMCS +12%.
Midday top 10 Losers: ECTE -31%. EBOD -28%. BCOV -23%. CKH -22%. LTM -20%. KERX -17%. CLSN -14%. SDR -14%. CBMX -11%. PXLW -11%. Comment! [On the Move]
Thursday, January 31, 10:07 AM Keryx Biopharmaceuticals (KERX) prices an offering of 8.2M shares at $8.49 each, which is where the stock closed yesterday. Including a greenshoe option of 1.2M shares, Keryx could raise up to $80.4M; the biotech plans to use the net proceeds to fund the launch of its kidney disease drug Zerenex. Shares +9.3% to $9.28. (PR) Comment! [Healthcare, On the Move]
Thursday, January 31, 9:13 AM Premarket gainers: ORCC +82%. WMS +55%. FTNT +20%. SGMS +15%. JDSU +14%. KERX +14%. ALGN +13%. SWKS +13%. CTXS +12%. ERIC +11%. DCTH +7%. PBI +8%. QCOM +6%. ALU +6%. CXS +6%. FNSR +6%. LVS +6%. UA +5%. IGT +5%.
Losers: CLSN -79%. LQDT -15%. FIO -14%. RIMM -7%. AFFY -7%. RMD -6%. FB -6%. VNR -5%. 1 Comment [On the Move]
Tuesday, January 29, 6:10 PM Keryx Biopharmaceuticals (KERX) announces a $55M secondary offering, with a 30-day option to the book-runner on another 15% of the number of shares sold. The company plans to use the net proceeds to fund its upcoming launch of Zerenex in Q2. J.P. Morgan is acting as the sole book-runner. Shares -7% AH. Comment! [Healthcare, On the Move]
Tuesday, January 29, 3:23 PM Shares of AEterna Zentaris (AEZS +18.5%) shares rocket higher in afternoon trading on the back of cancer drug peer Keryx Pharmaceuticals (KERX +40%) big gains. Volumes are extremely high in AEZS today, with over 4M shares changing hands, compared to the daily average of around 850K. 3 Comments [Healthcare, On the Move]
Tuesday, January 29, 12:45 PM Midday top 10 gainers: MLNK +32%. KERX +30%. SOMH +25%. VTUS +24%. MHH +14%. SWIR +14%. AEZS +11%. CNIT +11%. IBCP +10%. SSBI +10%.
Midday top 10 Losers: OXF -31%. ANAC -21%. VMW -20%. SANM -18%. OCZ -18%. LXK -15%. CTC -13%. GIG -12%. NTGR -11%. SHIP -11%. Comment! [On the Move]
Tuesday, January 29, 9:10 AM Premarket gainers: KERX +18%. PLXT +10%. VLO +8%. OPK +7%. HES +7%. RPRX +6%. AKS +6%.
Losers: OXF -24%. ANAC -23%. VMW -19%. LXK -6%. RBS -6%. STX -6%. EDU -5%. Comment! [On the Move]
Tuesday, January 29, 8:16 AM Keryx Biopharmaceuticals (KERX) up 10.6% premarket after yesterday's 77% rise, with Burrill almost doubling its price target to $11 following positive Phase 3 results for Zerenex. Stifel goes further, saying the drug's patent shelf life could translate into another $6-$14 of "tail" asset value. 1 Comment [Healthcare, On the Move]
Monday, January 28, 12:45 PM Midday top 10 gainers: KERX +79%. FURX +51%. SHIP +39%. CTC +18%. HGSH +17%. SINO +14%. RSH +12%. CPBC +11%. OCZ +11%. ACAD +10%.
Midday top 10 Losers: NVGN -61%. RPRX -27%. JOSB -18%. TRMD -16%. BYFC -15%. JVA -12%. DDD -11%. PRCP -10%. SSYS -9%. AKS -8%. Comment! [On the Move]
Monday, January 28, 9:11 AM Keryx Biopharmaceuticals (KERX) +45.4% premarket on news its Zerenex experimental kidney disease drug had met its late-stage trial goal of reducing phosphate levels in blood. KERX expects to submit a new drug application with the FDA and a marketing authorization application with the EMA for Zerenex in Q2. Comment! [Healthcare, On the Move]

dindin21
Good time to buy $KERX
Wed, 12:40 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$KERX breakout watch above 8.77 http://goo.gl/BbnRU
May 13, 3:27 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stocks to watch this week ... http://bit.ly/10QDENX ... $TROV, $AMRN, $SNWV.OB, $ANTB.OB, $APHY.OB, $KERX
May 12, 4:06 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
SanuWave Health $SNWV.OB - A price run with legs ... http://bit.ly/cAHZ42 ... $ANTB.OB, $MNKD, $KERX, $TTNP.OB, $ONVO.PK, $DDD
Apr 10, 10:00 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
SanuWave Health - A Price Run With Legs ... http://bit.ly/cAHZ42 ... $SNWV.OB, $ANTB.OB, $MNKD, $KERX, $TTNP.OB, $ONVO.PK, $DDD
Apr 10, 5:23 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

WhisperNumber
$KERX whisper number -$0.10. Price reaction data: http://bit.ly/XjLjKj
Mar 11, 3:45 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
$AEZS - Many gave Perifisone no chance after $KERX failure... Monday action likely the result of opportune shorts. http://bit.ly/cAHZ42
Mar 11, 1:37 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday ... $IMSC.PK, $AEZS, $KERX, $BBRY
Mar 6, 8:59 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Weekly Stock Watch: $IMSC.PK, $ANTB.OB, $FPMI.OB, $DIS, $MCD, $AZN, $TEV, $GSK, $KERX, $NVO, $AMRN - http://bit.ly/YJduvy
Mar 4, 7:16 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

StockConsultant
$KERX rising above 6.59 strong double support area, stock charts analysis http://goo.gl/4AsYf
Mar 1, 12:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Brad Kenagy
BillMauer $KERX 24.26%,MattSchilling $IMUC 21.43%,Isreal Shenker $KNDI 6.99%,EWBarnaba $ZTS 4.92%,mktlab68 $SRPT 4.33% http://bit.ly/TrJs0h
Feb 9, 1:49 PM
Reply (2)

• !Report Abuse
View all 2 replies
jsiebel720: & the value added here is what ????
Feb 13, 6:09 PM
• !Report Abuse
Brad Kenagy: It's a contest I am running to see who can provide Alpha by posting a positive return,and beat the $SPY.The link has the contest details.
Feb 13, 6:52 PM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$KERX, PT to $11 @ Burrill ("take out potential"), PT to $13 @ Stifel Nicolas This after huge move yesterday. (no position)
Jan 29, 8:04 AM
Reply (19)

• !Report Abuse
View all 19 replies
Perkins Cove: In my 2nd choice today....PLXT....need an updraft....Cheers.
Jan 29, 12:49 PM
• !Report Abuse
Closet Iguana: Won't pass it"s 52w high in the near term, will then move below $5.00 where it will stay til more positive medical news.
Feb 12, 10:59 PM
• !Report Abuse
Add a reply...

140 characters

Michael Fuller
BlockRock buy $QCOR (8% ownership) and $KERX (5% ownership) per SEC filings last week and this morning.
Feb 11, 7:13 AM
Reply (2)

• !Report Abuse
View all 2 replies
SKS1586: Awesome. Monday Pre-market starts with 2 Catalysts for QCOR.
Feb 11, 8:41 AM
• !Report Abuse
SKS1586: Awesome. Thanks a million. Monday morning starts with a great Catalyst for QCOR.
Feb 11, 8:55 AM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$KERX, re big drop Friday. Read the lungman comment........http://seekingalpha.com/n/h653
Feb 4, 8:59 AM
Reply (1)

• !Report Abuse
View all 1 replies
Perkins Cove: $7.16 to $7.68 so far today....hope you got the pop....it's now dropping lower....
Feb 4, 10:05 AM
• !Report Abuse
Add a reply...

140 characters

Jeff Pierce
$KERX powers higher. Shorting is a dangerous game w/ biotech stocks. http://stks.co/s1EZ
Jan 30, 2:24 PM
Reply (5)

• !Report Abuse
View all 5 replies
Perkins Cove: I do not have the intestinal fortatude to hold ANY Biotech overnight, without a cushion. That's just me.
Jan 30, 8:31 PM
• !Report Abuse
Robert Schwartz: It's like anything else, understanding engenders comfort. I was fortunate have spent many years analyzing biotech companies for Big Pharma.
Jan 31, 8:49 AM
• !Report Abuse
Add a reply...

140 characters

Perkins Cove
$KERX, congrats to longs!
Jan 28, 9:45 AM
Reply (3)

• !Report Abuse
View all 3 replies
Perkins Cove: Ya, I knew about in pre mkt, then forgot about it. Focus, focus, focus.......
Jan 28, 2:12 PM
• !Report Abuse
wheelz23: oh well, at least it verifies our daily stock picks are good
Jan 28, 2:21 PM
• !Report Abuse
Add a reply...

140 characters

smokeyRose
watching KERX and their drug Zerenex UGH! I'm still hanging with these guys. Hopefully it will pay off. was so much in the green. oh well
11/12/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: dont get your hopes high on a single drug...look into INO
11/12/12
• !Report Abuse
smokeyRose: I Did and have owned INO for some time now. I have high Hopes for this co. Yet also Believe KERX can pull a cat out of the Bag!
11/13/12
• !Report Abuse
Add a reply...

140 characters

iadops40
finally getting back to break even on KERX
9/21/12
Reply (3)

• !Report Abuse
View all 3 replies
iadops40: bought in Feb @ 3.08 prior to Perifosine run-up, then you know the rest LOL. Bullish Zerenex. I have been happy to see the recent...
9/21/12
• !Report Abuse
iadops40: ...uptrend and increased volume. I think we'll continue to see this uptrend to 4 by EOY, 5 might be pushing it, but its possible. GL 2 u.
9/21/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/28/12
Reply (2)

• !Report Abuse
View all 2 replies
iadops40: http://bit.ly/RntWCr
8/28/12
• !Report Abuse
DAG1996: thanks for sharing that.
8/28/12
• !Report Abuse
Add a reply...

140 characters

iadops40
Huge all-star biotech conference (Rodman & Renshaw) in New York Sept. 9-11 CLSN GALE GERN IBIO INO KERX NVAX NBS ONTY VVUS
8/27/12
Reply (1)

• !Report Abuse
View all 1 replies
iadops40: http://bit.ly/RntWCr
8/27/12
• !Report Abuse
Add a reply...

140 characters

The Scientist
KERX should not have given away perifosine rights to AEZS. Strongest data is for r/r MM. Study headed by Dr. Richardson at Dana-Farber
6/5/12
Reply (1)

• !Report Abuse
View all 1 replies
The Scientist: Dr Richardson director of MM at Dana-F. He is not dumb enough to waste his time-effort if perifosine had NO possible chance of working
6/5/12
• !Report Abuse
Add a reply...

140 characters

Victoria70
$KERX is making a move now! So, is $BPAX up from .34 closed around .53. Any advice on these two stock would be greatly appreciated. Thanks
5/21/12
Reply (5)

• !Report Abuse
View all 5 replies
iadops40: rule no. 1 ...don't get greedy with biotech, take profits
5/21/12
• !Report Abuse
iadops40: analyst sentiment is a 4 target with a high target of 7
5/21/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
http://bit.ly/Kv65tO KERX back from the dead
5/2/12
Reply (1)

• !Report Abuse
View all 1 replies
Winning Will: huge bids coming in on KERX.. Could be more insider buying
5/3/12
• !Report Abuse
Add a reply...

140 characters

Winning Will
KERX could be ready to pop.. still oversold imo
4/30/12
Reply (9)

• !Report Abuse
View all 9 replies
iadops40: thanks Will, yeah I was riding the KERX pump wave up 75% got greedy and didnt sell or at least take profit, last time I make that mistake.
4/30/12
• !Report Abuse
iadops40: KERX is on their last leg with Zerenex, but this one looks promising, all signs look good, as long as good phase III and FDA approval $4-5
4/30/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://t.co/J5W5mLXX Earning after hour $AMZN $CHH $CSTR $DECK $ DLA $EXPE $GILD $ITMN $MBLX $LEAP $KERX $MET $SWKS $SBUX $TNAV $VRSN $ZNGA
4/26/12
Reply (3)

• !Report Abuse
View all 3 replies
Winning Will: I do not believe KERX is reporting earnings AH.. Where did you get this info
4/26/12
• !Report Abuse
freefdawatchlist: I use http://bit.ly/I8MGxZ It shows KERX earning after hours 5. pm EST
4/26/12
• !Report Abuse
Add a reply...

140 characters

KERX Keryx Biopharmaceuticals, Inc.

KERX

Keryx Biopharmaceuticals, Inc.